GlassScriptPhysician profile
Helen A Davis
NPI 1700861762
$1,302.15
in general payments reported to CMS, 2019-2025
14 companies · $555 in 2025
The $555 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2021: $215 · 2022: $179 · 2023: $219 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $321.46 | 2025 | M22 |
| Dompe US, INC. | $239.38 | 2021-2025 | Oxervate |
| Glaukos Corporation | $138.08 | 2025 | Idosetr |
| Eyepoint US, INC. | $124.10 | 2021 | |
| Viiv Healthcare Company | $123.06 | 2023 | Apretude |
| Biotissue Holdings INC. | $83.66 | 2019 | |
| Genentech USA, INC. | $71.90 | 2022 | |
| Carl Zeiss Meditec, INC. | $58.44 | 2021 | |
| Mallinckrodt Hospital Products INC. | $33.07 | 2022 | |
| Novartis Pharmaceuticals Corporation | $29.49 | 2019 | |
| Sun Pharmaceutical Industries INC. | $22.97 | 2022 | |
| Astellas Pharma US INC | $21.72 | 2019 | |
| Alcon Vision LLC | $18.41 | 2022 | |
| Aerie Pharmaceuticals, INC. | $16.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.